The current Research Society for the Study of Diabetes in India (RSSDI)-Endocrine Society of India (ESI) clinical practice guidelines recommend DPP-4 inhibitors as second-line therapy as an add-on to metformin if glucose control targets are not achieved with metformin monotherapy [37]. Here, DPP4 is linked to diabetes mellitus.